The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and ...

Nicole A. Cipriani, MD, offers guidance for community oncologists regarding the role of BRAF p.V600E testing in patients with papillary thyroid carcinoma.

Hardeep Phull, MD, shared how telemedicine has transformed access, improved patient experience, and redefined care delivery for patients with cancer.

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI ...